ROMUALDO BARROSO DE SOUSA (BRA)
Clinical Oncologist, Head of Research in Oncology and National Leader of Breast Cancer – DASA Oncology. Postdoc at the Dana-Farber Cancer Institute/Harvard Medical School
WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER
WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER
FACE-TO-FACE
GRUPO ONCOCLÍNICAS
Coordinators:
CRISTIANO AUGUSTO ANDRADE DE RESENDE (BRA)
LEANDRO GONÇALVES OLIVEIRA (BRA)
ROMUALDO BARROSO DE SOUSA (BRA)
VICTOR DOMINGOS LISITA ROSA (BRA)
WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER
Thinking outside the box in the advanced disease: new biomarkers and immunotherapy indications
WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER
PART 4 - ADCs
Coordinator:
ROMUALDO BARROSO DE SOUSA (BRA)
WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER
What’s next in terms of breast cancer treatment with ADCs
BREAST CANCER PRECEPTORY | MASTERCLASS
When can we use genomic signatures to predict the benefit of chemotherapy in patients with HR-positive, HER-2-negative luminal disease?
MAIN AUDITORIUM
Mini conference: The treatment future of hormone positive advanced breast cancer
Chairman:
GABRIEL FELIPE SANTIAGO (BRA)
Speaker:
ROMUALDO BARROSO DE SOUSA (BRA)
CLINICAL RESEARCH WORKSHOP
Is there any difference in conducting a phase 1 trial?
ROMUALDO BARROSO DE SOUSO (BRA)
1) Which barriers must be broken?
2) What are the greatest concerns in phase 1 trials?
3) Tips: how to persuade the sponsor that your center is ready for a phase 1 trial?
